The current UK standard of care in early-stage (node-negative) oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer is surgery followed by adjuvant endocrine therapy, with or without the addition of systemic chemotherapy [4, 5]. The gene discussed is ERBB2; the disease is breast cancer.